Renal Cancer - Results from #440

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001. March 21, 2024

Designing a predictive Framework: Immune-Related Gene-Based nomogram and prognostic model for kidney renal papillary cell carcinoma. March 21, 2024

The role of RNA-modifying proteins in renal cell carcinoma. March 21, 2024

TNM-based risk eligibility for adjuvant trials in renal cell carcinoma. March 21, 2024

Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer? March 21, 2024

Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence? March 21, 2024

Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis. March 20, 2024

Renal mass imaging modalities: does body mass index (BMI) matter? March 20, 2024

Integrative Analysis of Germline Rare Variants in Clear and Non-clear Cell Renal Cell Carcinoma. March 19, 2024

The Impact of Histological Variants on Oncological Outcomes After Surgical Resection of a Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus: A Multi-institutional Study. March 19, 2024

Prognostic factors of renal cell cancer in elderly patients: a population-based cohort study. March 18, 2024

Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. March 18, 2024

Stratification of Patients with Renal Cell Carcinoma by the Abundance of Sarcomatoid Features Reveals Differences in Survival and the Underlying Pathobiology. March 15, 2024

Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. March 15, 2024

A contemporary comparison of laparoscopic versus open partial nephrectomy for renal cell carcinoma. March 14, 2024

A network meta-analysis evaluating the efficacy and safety of adjuvant therapy after nephrectomy in renal cell carcinoma. March 14, 2024

L1CAM Expression and Molecular Alterations Distinguish Low Grade Oncocytic Tumor (LOT) from Eosinophilic Chromophobe Renal Cell Carcinoma. March 13, 2024

Characterization of renal masses with MRI-based radiomics: assessment of inter-package and inter-observer reproducibility in a prospective pilot study. March 13, 2024

The Prevalence and Radiologic Features of Renal Cancers Associated with FLCN, BAP1, SDH, and MET Germline Mutations. March 12, 2024

Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis. March 12, 2024

Page 23 of 456